Embolic stroke of undetermined source (ESUS) is an embolic stroke, a type of ischemic stroke, with an unknown origin,[1] defined as a non-lacunar brain infarct without proximal arterial stenosis or cardioembolic sources.[2] As such, it forms a subset of cryptogenic stroke, which is part of the TOAST-classification.[3] The following diagnostic criteria define an ESUS:[2]

Signs and symptoms

This section is empty. You can help by adding to it. (December 2021)

Causes

The following factors are suggested as pathogenesis of ESUS:[4]

Diagnosis

ESUS is a diagnosis of exclusion based on radiological and cardiological examinations. For exclusion of haemorrhagic or lacunar strokes CT or MRI imaging is needed. Both procedures also allow detection of embolic pattern of ischemic lesions. 12-lead ECG and cardiac monitoring for at least 24 h with automated rhythm detection are mandated to exclude atrial fibrillation; echocardiography (TTE and/or TEE) is used to detect other major-risk cardioembolic sources (e.g., intracardiac thrombi, or ejection fraction <30%). For imaging of both the extracranial and intracranial arteries supplying the area of brain ischaemia, examination methods like catheter, MR/CT angiography or cervical duplex plus transcranial Doppler ultrasonography are required. They allow an exclusion of large vessel stenosis (≥ 50%).[2]

Cryptogenic stroke vs ESUS

Cryptogenic stroke is also an ischemic stroke with more than one probable cause or strokes with incomplete diagnostic workup.[3] ESUS has a clearer definition, with an established minimum diagnostic requirements; this is not required in defining a cryptogenic stroke. ESUS is an embolic stroke for which no probable cause can be identified after a standard diagnostic evaluation.[citation needed]

Management

Due to the lack of data, there are no specific treatment guidelines for ESUS. Current guidelines recommend antiplatelet therapy for patients with non-cardioembolic ischemic stroke.[8][9][10] However, it is widely believed that there is a substantial overlap between ESUS and cardioembolic stroke, clinical trials have assessed the benefit of anticoagulation versus antiplatelet agents for preventing recurrent stroke.[2][11] Although the existing data does not favor the use anticoagulation in patients with ESUS, current hypotheses suggest there may be subgroups who do benefit from anticoagulation.[12]

Epidemiology

On average, ESUS accounts for about 1 in 6 ischemic strokes (17% (range 9 – 25%)) according to a systematic literature review of 9 studies.[13] Patients with ESUS tend to be relatively young and experience mild strokes. However, ESUS is associated with high recurrence rates. Of 2045 ESUS patients (identified by 8 studies)

The stroke recurrence rate was 29.0% over 5 years in patients with ESUS, which is similar to patients with cardioembolic stroke (26.8%), but significantly higher than all types of non-cardioembolic stroke. However, mortality was significantly lower in patients with ESUS than cardioembolic stroke.[14][15]

References

  1. ^ Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ (April 2017). "Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update". Stroke. 48 (4): 867–872. doi:10.1161/STROKEAHA.116.016414. PMID 28265016. S2CID 3679562.
  2. ^ a b c d Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O'Donnell MJ, Sacco RL, Connolly SJ (April 2014). "Embolic strokes of undetermined source: the case for a new clinical construct". The Lancet. Neurology. 13 (4): 429–38. doi:10.1016/S1474-4422(13)70310-7. PMID 24646875. S2CID 36116833.
  3. ^ a b Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE (January 1993). "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment". Stroke. 24 (1): 35–41. doi:10.1161/01.STR.24.1.35. PMID 7678184.
  4. ^ a b Nouh A, Hussain M, Mehta T, Yaghi S (2016). "Embolic Strokes of Unknown Source and Cryptogenic Stroke: Implications in Clinical Practice". Frontiers in Neurology. 7: 37. doi:10.3389/fneur.2016.00037. PMC 4800279. PMID 27047443.
  5. ^ Freilinger TM, Schindler A, Schmidt C, Grimm J, Cyran C, Schwarz F, et al. (April 2012). "Prevalence of nonstenosing, complicated atherosclerotic plaques in cryptogenic stroke". JACC: Cardiovascular Imaging. 5 (4): 397–405. doi:10.1016/j.jcmg.2012.01.012. PMID 22498329.
  6. ^ Gupta A, Gialdini G, Lerario MP, Baradaran H, Giambrone A, Navi BB, et al. (June 2015). "Magnetic resonance angiography detection of abnormal carotid artery plaque in patients with cryptogenic stroke". Journal of the American Heart Association. 4 (6): e002012. doi:10.1161/JAHA.115.002012. PMC 4599540. PMID 26077590.
  7. ^ Amarenco P, Cohen A, Tzourio C, Bertrand B, Hommel M, Besson G, et al. (December 1994). "Atherosclerotic disease of the aortic arch and the risk of ischemic stroke". The New England Journal of Medicine. 331 (22): 1474–9. doi:10.1056/NEJM199412013312202. PMID 7969297.
  8. ^ European Stroke Organisation (ESO) Executive Committee, Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, et al. (July 2014). "Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association". Stroke. 45 (7): 2160–236. doi:10.1161/STR.0000000000000024. PMID 24788967.
  9. ^ Lansberg MG, O'Donnell MJ, Khatri P, Lang ES, Nguyen-Huynh MN, Schwartz NE, et al. (February 2012). "Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e601S–e636S. doi:10.1378/chest.11-2302. PMC 3278065. PMID 22315273.
  10. ^ European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee, Ringleb PA, Bousser MG, Ford G, Bath P, Brainin M, et al. (2008). "Guidelines for management of ischaemic stroke and transient ischaemic attack 2008". Cerebrovascular Diseases. 25 (5): 457–507. doi:10.1159/000131083. PMID 18477843.
  11. ^ Kamel H, Healey JS (February 2017). "Cardioembolic Stroke". Circulation Research. 120 (3): 514–526. doi:10.1161/CIRCRESAHA.116.308407. PMC 5312810. PMID 28154101.
  12. ^ Greeve, Isabell; Schäbitz, Wolf-Rüdiger (May 2022). "Embolic stroke of undetermined source: identification of patient subgroups for oral anticoagulation treatment". Neural Regeneration Research. 17 (5): 1005–1006. doi:10.4103/1673-5374.324837. ISSN 1673-5374. PMC 8552842. PMID 34558521.
  13. ^ Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ (April 2017). "Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update". Stroke. 48 (4): 867–872. doi:10.1161/STROKEAHA.116.016414. PMID 28265016.
  14. ^ Ntaios G, Papavasileiou V, Milionis H, Makaritsis K, Manios E, Spengos K, Michel P, Vemmos K (January 2015). "Embolic strokes of undetermined source in the Athens stroke registry: a descriptive analysis". Stroke. 46 (1): 176–81. doi:10.1161/STROKEAHA.114.007240. PMID 25378429.
  15. ^ Ntaios G, Papavasileiou V, Milionis H, Makaritsis K, Vemmou A, Koroboki E, et al. (August 2015). "Embolic Strokes of Undetermined Source in the Athens Stroke Registry: An Outcome Analysis". Stroke. 46 (8): 2087–93. doi:10.1161/STROKEAHA.115.009334. PMID 26159795. S2CID 1486434.

Further reading

Categories